Citations for
1CDKN2B, STAU1, TINCR
E2F1 induces TINCR transcriptional activity and accelerates gastric cancer progression via activation of TINCR/STAU1/CDKN2B signaling axis.
Xu TP, Wang YF, Xiong WL, Ma P, Wang WY, Chen WM, Huang MD, Xia R, Wang R, Zhang EB, Liu YW, De W, Shu YQ.
Cell Death Dis 8(6):e2837. doi: 10.1038/cddis.2017.205. 2017
2CDKN2B
CDKN2B Regulates TGFβ Signaling and Smooth Muscle Cell Investment of Hypoxic Neovessels.
Nanda V, Downing KP, Ye J, Xiao S, Kojima Y, Spin JM, DiRenzo D, Nead KT, Connolly AJ, Dandona S, Perisic L, Hedin U, Maegdefessel L, Dalman J, Guo L, Zhao X, Kolodgie FD, Virmani R, Davis HR Jr, Leeper NJ.
Circ Res 118(2):230-40. doi: 10.1161/CIRCRESAHA.115.307906. Epub 2015 Nov 23. 2016
3CDKN2B
Hypermethylation of p15 gene associated with an inferior poor long-term outcome in childhood acute lymphoblastic leukemia.
Mai H, Liu X, Chen Y, Li C, Cao L, Chen X, Chen S, Liu G, Wen F.
J Cancer Res Clin Oncol 142(2):497-504. 2016
4CDKN2A, CDKN2B
Oxidative stress levels are correlated with P15 and P16 gene promoter methylation in myelodysplastic syndrome patients.
Gonçalves AC, Cortesão E, Oliveiros B, Alves V, Espadana AI, Rito L, Magalhães E, Pereira S, Pereira A, Costa JM, Mota-Vieira L, Sarmento-Ribeiro AB.
Clin Exp Med 16(3):333-43. doi: 10.1007/s10238-015-0357-2. Epub 2015 May 17. 2016
5ASXL1, CDKN2B
Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals.
Wu X, Bekker-Jensen IH, Christensen J, Rasmussen KD, Sidoli S, Qi Y, Kong Y, Wang X, Cui Y, Xiao Z, Xu G, Williams K, Rappsilber J, Sønderby CK, Winther O, Jensen ON, Helin K.
Cell Res 25(11):1205-18. doi: 10.1038/cr.2015.121. 2015
6CDKN2A, CDKN2B, STAT5B
Control of CD8 T cell proliferation and terminal differentiation by active STAT5 and CDKN2A/CDKN2B.
Grange M, Giordano M, Mas A, Roncagalli R, Firaguay G, Nunes JA, Ghysdael J, Schmitt-Verhulst AM, Auphan-Anezin N.
Immunology 145(4):543-57. doi: 10.1111/imm.12471. Epub 2015 Jun 15. 2015
7CDKN2B
Germline Mutations in the CDKN2B Tumor Suppressor Gene Predispose to Renal Cell Carcinoma.
Jafri M, Wake NC, Ascher DB, Pires DE, Gentle D, Morris MR, Rattenberry E, Simpson MA, Trembath RC, Weber A, Woodward ER, Donaldson A, Blundell TL, Latif F, Maher ER.
Cancer Discov 5(7):723-9. doi: 10.1158/2159-8290.CD-14-1096. Epub 2015 Apr 14. 2015
8CDKN1B, CDKN2B, RB1, SMAD2
Smad2 overexpression reduces the proliferation of the junctional epithelium.
Alotaibi MK, Kitase Y, Shuler CF.
J Dent Res 93(9):898-903. doi: 10.1177/0022034514543016. Epub 2014 Jul 14. 2014
9CDKN2A, CDKN2B
Aberrant promoter methylation of p15 (INK⁴b) and p16 (INK⁴a) genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis.
Wang X, Zhu YB, Cui HP, Yu TT.
Tumour Biol 35(9):9035-43. doi: 10.1007/s13277-014-2054-2. Epub 2014 Jun 8. 2014
10CDKN2B
Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis.
Kojima Y, Downing K, Kundu R, Miller C, Dewey F, Lancero H, Raaz U, Perisic L, Hedin U, Schadt E, Maegdefessel L, Quertermous T, Leeper NJ.
J Clin Invest 124(3):1083-97. doi: 10.1172/JCI70391. Epub 2014 Feb 17. 2014
11CDKN1B, CDKN2B, KDM2A
Depletion of histone demethylase KDM2A inhibited cell proliferation of stem cells from apical papilla by de-repression of p15INK4B and p27Kip1.
Gao R, Dong R, Du J, Ma P, Wang S, Fan Z.
Mol Cell Biochem 379(1-2):115-22. doi: 10.1007/s11010-013-1633-7. Epub 2013 Apr 5. 2013
12CDKAL1, CDKN2A, CDKN2B
The relationship between five widely-evaluated variants in CDKN2A/B and CDKAL1 genes and the risk of type 2 diabetes: a meta-analysis.
Peng F, Hu D, Gu C, Li X, Li Y, Jia N, Chu S, Lin J, Niu W.
Gene 531(2):435-43. doi: 10.1016/j.gene.2013.08.075. Epub 2013 Sep 4. 2013
13CDKN2B
Loss of CDKN2B promotes p53-dependent smooth muscle cell apoptosis and aneurysm formation.
Leeper NJ, Raiesdana A, Kojima Y, Kundu RK, Cheng H, Maegdefessel L, Toh R, Ahn GO, Ali ZA, Anderson DR, Miller CL, Roberts SC, Spin JM, de Almeida PE, Wu JC, Xu B, Cheng K, Quertermous M, Kundu S, Kortekaas KE, Berzin E, Downing KP, Dalman RL, Tsao PS, Schadt EE, Owens GK, Quertermous T.
Arterioscler Thromb Vasc Biol 33(1):e1-e10. doi: 10.1161/ATVBAHA.112.300399. Epub 2012 Nov 15. 2013
14CDKN2A, CDKN2B, DLC1
Inactivation of the Dlc1 gene cooperates with downregulation of p15INK4b and p16Ink4a, leading to neoplastic transformation and poor prognosis in human cancer.
Qian X, Durkin ME, Wang D, Tripathi BK, Olson L, Yang XY, Vass WC, Popescu NC, Lowy DR.
Cancer Res 72(22):5900-11. doi: 10.1158/0008-5472.CAN-12-2368. Epub 2012 Sep 25. 2012
15CDKN2B, MBD4, TDG, ZNF217
TGF-β-dependent active demethylation and expression of the p15ink4b tumor suppressor are impaired by the ZNF217/CoREST complex.
Thillainadesan G, Chitilian JM, Isovic M, Ablack JN, Mymryk JS, Tini M, Torchia J.
Mol Cell 46(5):636-49. doi: 10.1016/j.molcel.2012.03.027. Epub 2012 May 3. 2012
16CDKN2B, CDKNA
Molecular characterization of 9p21 deletions shows a minimal common deleted region removing CDKN2A exon 1 and CDKN2B exon 2 in diffuse large B-cell lymphomas.
Guney S, Bertrand P, Jardin F, Ruminy P, Kerckaert JP, Tilly H, Bastard C.
Genes Chromosomes Cancer 50(9):715-25. doi: 10.1002/gcc.20893. Epub 2011 Jun 2. 2011
17CDKN2A, CDKN2B, CDKN2B-AS1
Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression.
Cunnington MS, Santibanez Koref M, Mayosi BM, Burn J, Keavney B.
PLoS Genet 6(4):e1000899. 2010
18CDKN2B, GFI1, ZBTB17
Gfi-1 represses CDKN2B encoding p15INK4B through interaction with Miz-1.
Basu S, Liu Q, Qiu Y, Dong F.
Proc Natl Acad Sci U S A 106(5):1433-8. Epub 2009 Jan 22. 2009
19CDKN2B, RTEL1, TNFRSF6B
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility.
Wrensch M, Jenkins RB, Chang JS, Yeh RF, Xiao Y, Decker PA, Ballman KV, Berger M, Buckner JC, Chang S, Giannini C, Halder C, Kollmeyer TM, Kosel ML, LaChance DH, McCoy L, O'Neill BP, Patoka J, Pico AR, Prados M, Quesenberry C, Rice T, Rynearson AL, Smirnov I, Tihan T, Wiemels J, Yang P, Wiencke JK.
Nat Genet 41(8):905-8. Epub 2009 Jul 5.PMID: 19578366 2009
20CDKN2A, CDKN2B
Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study.
Kim M, Yim SH, Cho NS, Kang SH, Ko DH, Oh B, Kim TY, Min HJ, She CJ, Kang HJ, Shin HY, Ahn HS, Yoon SS, Kim BK, Shin HR, Han KS, Cho HI, Lee DS.
Cancer Genet Cytogenet 195(1):59-65.PMID: 19837270 2009
21CDKN2B
p15 promoter methylation - a novel prognostic marker in glioblastoma patients.
Wemmert S, Bettscheider M, Alt S, Ketter R, Kammers K, Feiden W, Steudel WI, Rahnenführer J, Urbschat S.
Int J Oncol 34(6):1743-8.PMID: 19424593 2009
22CDKN2A, CDKN2B
Different molecular mechanisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood.
Novara F, Beri S, Bernardo ME, Bellazzi R, Malovini A, Ciccone R, Cometa AM, Locatelli F, Giorda R, Zuffardi O.
Hum Genet 126(4):511-20. Epub 2009 May 30.PMID: 19484265 2009
23CDKN2B
Clinical risk factors, DNA variants, and the development of type 2 diabetes.
Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, Berglund G, Altshuler D, Nilsson P, Groop L.
N Engl J Med 359(21):2220-32.PMID: 19020324 2008
24CDKN2B, IGFBP2, CDKAL1, NIDDM18
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.
Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research, Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, Hughes TE, Groop L, Altshuler D, Almgren P, Florez JC, Meyer J, Ardlie K, Bengtsson Bostrom K, Isomaa B, Lettre G, Lindblad U, Lyon HN, Melander O, Newton-Cheh C, Nilsson P, Orho-Melander M, Rastam L, Speliotes EK, Taskinen MR, Tuomi T, Guiducci C, Berglund A, Carlson J, Gianniny L, Hackett R, Hall L, Holmkvist J, Laurila E, Sjogren M, Sterner M, Surti A, Svensson M, Svensson M, Tewhey R, Blumenstiel B, Parkin M, Defelice M, Barry R, Brodeur W, Camarata J, Chia N, Fava M, Gibbons J, Handsaker B, Healy C, Nguyen K, Gates C, Sougnez C, Gage D, Nizzari M, Gabriel SB, Chirn GW, Ma Q, Parikh H, Richardson D, Ricke D, Purcell S.
Science 316(5829):1331-6. Epub 2007 Apr 26. 2007
25CDKN2A,CDKN2B
A common allele on chromosome 9 associated with coronary heart disease.
McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hobbs HH, Cohen JC.
Science 316(5830):1488-91. Epub 2007 May 3. 2007
26CDKN2A,CDKN2B, ANRIL
A common variant on chromosome 9p21 affects the risk of myocardial infarction.
Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, Jonasdottir A, Sigurdsson A, Baker A, Palsson A, Masson G, Gudbjartsson DF, Magnusson KP, Andersen K, Levey AI, Backman VM, Matthiasdottir S, Jonsdottir T, Palsson S, Einarsdottir H, Gunnarsdottir S, Gylfason A, Vaccarino V, Hooper WC, Reilly MP, Granger CB, Austin H, Rader DJ, Shah SH, Quyyumi AA, Gulcher JR, Thorgeirsson G, Thorsteinsdottir U, Kong A, Stefansson K.
Science 316(5830):1491-3. Epub 2007 May 3. 2007
27CDKN2A, CDKN2B, MNST
Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.
Laud K, Marian C, Avril MF, Barrois M, Chompret A, Goldstein AM, Tucker MA, Clark PA, Peters G, Chaudru V, Demenais F, Spatz A, Smith MW, Lenoir GM, Bressac-de Paillerets B; French Hereditary Melanoma Study Group.
J Med Genet 43(1):39-47. Epub 2005 Jun 3. 2006
28CDKN2A, CDKN2B
The regulation of INK4/ARF in cancer and aging.
Kim WY, Sharpless NE.
Cell 127(2):265-75. Review. 2006
29CDKN2A, CDKN2B
Loss of 9p21 is embedded in a complex but consistent pattern of genomic imbalances in oral squamous cell carcinomas.
Gebhart E, Liehr T, Wolff E, Wiltfang J, Koscielny S, Ries J.
Cytogenet Genome Res 101(2):106-12. 2003
30CDKN2A, CDKN2B
Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors.
Arcellana-Panlilio MY, Egeler RM, Ujack E, Magliocco A, Stuart GC, Robbins SM, Coppes MJ.
Genes Chromosomes Cancer 35(2):176-81. 2002
31CDKN2A, CDKN2B, MNST
A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family.
Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, Sibley K, Whitaker L, Knowles M, Newton Bishop J , Bishop DT.
Hum Mol Genet 10(1):55-62. 2001
32CDKN2A, CDKN2B
Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas.
Bisogna M, Calvano JE, Ho GH, Orlow I, Cordon-Cardo C, Borgen PI, Van Zee KJ.
Cancer Genet Cytogenet 125(2):131-8. 2001
33CDKN2A, CDKN2B
Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, Kaneko Y.
Cancer Genet Cytogenet 120(2):91-8. 2000
34CDKN2A, CDKN2B
Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival.
Orlow I, et al.
J Natl Cancer Inst 91(1):73-9. 1999
35CDKN2A, CDKN2B, IFN1@, TSG9A
Identification and characterization of a homozygous deletion found in ovarian ascites by representational difference analysis.
Watson JEV, et al.
Genome Res 9(3):226-33. 1999
36CDKN2B
Prognostic role of p27Kip1 and apoptosis in human breast cancer.
Wu J, et al.
Br J Cancer 79(9-10):1572-8. 1999
37CDKN2A, CDKN2B
Acquisition of p16(INK4A) and p15(INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia.
Maloney KW, et al.
Blood 93(7):2380-5. 1999
38CDKN2A, CDKN2B
Functional evidence for a role of combined CDKN2A (p16-p14(ARF))/CDKN2B (p15) gene inactivation in malignant gliomas.
Simon M, Koster G, Menon AG, Schramm J.
Acta Neuropathol (Berl) 98(5):444-52 1999
39CDKN2A, CDKN2B
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Walker GJ, et al.
Genes Chromosomes Cancer 22 : 157-163. 1998
40CDKN2A, CDKN2B, CMM2, TSG9A
Mutations of p16 and p15 tumor suppressor genes and replication errors contribute independently to the pathogenesis of sporadic malignant melanoma.
Matsumura Y, et al.
Arch Dermatol Res 290 : 175-180. 1998
41CDKN2A, CDKN2B, CDKN2C, CDKN2D
Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells.
Drexler HG.
Leukemia 12 : 845-859. 1998
42CDKN2B, CMM2
Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma.
Elenitoba-Johnson KS, et al.
Blood 91 : 4677-4685. 1998
43CDKN2A, CDKN2B, HLF, TCF3
Different patterns of homozygous p16INK4A and P15INK4B deletions in childhood acute lymphoblastic leukemias containing distinct E2A translocations.
Maloney KW, et al.
Leukemia 12 : 1417-1421. 1998
44CDKN2B
High-risk myelodysplastic syndromes and hypermethylation of the p15Ink4B gene.
Uchida T, et al.
Leuk Lymphoma 32(1-2):9-18. 1998
45CDKN2A, CDKN2B, MNST
Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors.
Bahuau M, Vidaud D, Jenkins RB, Bieche I, Kimmel DW, Assouline B, Smith JS, Alderete B, Cayuela JM, Harpey JP, Caille B, Vidaud M.
Cancer Res 58(11):2298-303. 1998
46CDKN2A, CDKN2B, CMM2
Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF.
Liu L, et al.
Genes Chromosomes Cancer 19 : 52-54. 1997
47CDKN2A, CDKN2B, TSG9A
Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes.
Farrell WE, Simpson DJ, Bicknell JE, Talbot AJ, Bates AS, Clayton RN.
Cancer Res 57(13):2703-9. 1997
48CDKN2B
Cloning and characterization of p10, an alternatively spliced form of p15 cyclin-dependent kinase inhibitor.
Tsubari M, Tiihonen E, Laiho M.
Cancer Res 57(14):2966-73. 1997
49CDKN2A, CDKN2B, TSG9A
Disruption of the multiple tumor suppressor gene MTS1/p16(INK4a)/CDKN2 by illegitimate V(D)J recombinase activity in T-cell acute lymphoblastic leukemias.
Cayuela JM, Gardie B, Sigaux F.
Blood 90(9):3720-6. 1997
50CDKN2A, CDKN2B, CDKN2C, TSG9A
Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, andCDKN2C) in childhood rhabdomyosarcoma.
Iolascon A, et al.
Genes Chromosomes Cancer 15 : 217-222. 1996
51D9S974, D9S975, D9S976, D9S977, D9S978, CDKN2A, CDKN2B, TSG9A
Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma.
Ohta M, et al.
Int J Cancer 65 : 762-767. 1996
52CDKN2A, CDKN2B, CMM2, TSG9A
Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas.
Jagasia AA, et al.
Cancer Lett 105 : 91-103. 1996
53CDKN2A, CDKN2B, TSG9A
Deletion of CDK4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma. (abstr)
Koduru PRK, et al.
Blood 86(8):2900-5. 1995
54TSG9A, CDKN2A, CDKN2B
Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers.
Suzuki H, Zhou X, Yin J, Lei J, Jiang HY, Suzuki Y, Chan T, Hannon GJ, Mergner WJ, Abraham JM, et al.
Hum Mol Genet 4(10):1883-7. 1995
55CDKN2D, CDKN2A, CDKN2B
Molecular cloning, expression pattern, and chromosomal localization of human CDKN2D/INK4d an inhibitor of cyclin D-dependent kinases.
Okuda T, Hirai H, Valentine VA, Shurtleff SA, Kidd VJ, Lahti JM, Sherr CJ, Downing JR.
Genomics 29(3):623-30. 1995
56TSG9A, CDKN2B
Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient.
Glendening JM, et al.
Cancer Res 55 : 5531-5535. 1995
57CDKN2A, CDKN2B, TSG9A
Loss of heterozygosity at 9p21 loci and mutations of the MTS1 and MTS2 genes in human lung cancers.
Shimizu T, et al.
Int J Cancer 63 : 616-620. 1995
58TSG9A, CDKN2A, CDKN2B
Codeletion of p15 and p16 in primary malignant mesothelioma.
Xiao S, et al.
Oncogene 11 : 511-515. 1995
59CDKN2A, CDKN2B
Candidate tumor-suppressor genes MTS1 (p16ink4A) and MTS2 (p15ink4B) display frequent homozygous deletions in primary cells from T-but not from B-cell lineage acute lymphoblastic leukemias.
Hebert J, et al.
Blood 84 : 4038-4044. 1994
60TSG9A, CDKN2A, CDKN2B
Deletion of p16 and p15 genes in brain tumors.
Jen J, et al.
Cancer Res 54 : 6353-6358. 1994
61CDKN2B, CDKN2C
Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function.
Guan KL, et al.
Genes Dev 8 : 2939-2952. 1994